Ray Bailey, RPh: Complexities With Biosimilars

Transcript:

What is your practice’s experience with biosimilars?

I am involved, and yes, there will be an uptake of biosimilars in my practice, I’m sure. We’re talking to those companies. There are some complexities around, you know, reimbursement, so—we’ll kind of just have to wait and see. But I think we’re looking forward to more and more biosimilars coming to market. With us being in all these value-based contracts, I’m sure it’s going to come into play in the way our practice sets up our formularies and pathways.